Decision-making for Pediatric Allergy Immunotherapy for Aeroallergens: a Narrative Review

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2019 Aug 16

PMID 31414212

Citations 5

Authors

Miguel Tortajada-Girbes

Maria Mesa Del Castillo

Helena Larramona

Jose Manuel Lucas

Montserrat Alvaro Lozano

Ana Isabel Tabar

Begona Soler Lopez

Ana Martinez-Canavate

Affiliations

Soon will be listed here.

Abstract

There has been exciting progress in diagnosis and in the treatment of allergic patients. The objective of this review is to summarize the most relevant contributions in the past 10 years with a special focus on the pediatric population allergic to aeroallergens and provide the most relevant references and practical issues for the decision-making. Current guidelines on allergy diagnosis recommend a thorough clinical history as the first step, followed by allergen extract testing using an in vivo prick test and/or an in vitro specific IgE test. Molecular diagnosis is recommended when previous tests are inconclusive. In practice, the most important factors to decide the AIT treatment are the actual intensity and duration of the patient's symptoms and the availability of appropriate AIT products for the patient's sensitization profile at high allergen concentrations and with confirmed efficacy and safety from clinical trials. This document summarizes outstanding references for allergic immunotherapy decision-making and provides summary tables and figures analyzing the most important factors related to the decision for allergen immunotherapy and the safety risks related. The experts concluded that AIT is efficacious and safe for the treatment of allergic patients that is available for the most frequent aeroallergens.What is Known:• The prevalence of allergic asthma and rhinitis in children has increased in recent decades.• The efficacy and safety of allergen immunotherapy has been shown in multiple studies and systematic reviews.What is New:• This document summarizes outstanding references for allergic immunotherapy decision-making and provides summary tables and figures analyzing the most important factors related to the decision for allergen immunotherapy and the safety risks related. Recommendations of expert authors for the decision of the patients more suitable for allergen immunotherapy are included.

Citing Articles

VALIDA project: Validation of allergy diagnostics assays (Tools and recommendations for the assessment of tests in the diagnosis of allergy).

Casas M, Esteban A, Gonzalez-Munoz M, Labrador-Horrillo M, Pascal M, Teniente-Serra A Adv Lab Med. 2023; 1(4):20200051.

PMID: 37360620 PMC: 10197418. DOI: 10.1515/almed-2020-0051.

Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy.

Mormile I, Granata F, Detoraki A, Pacella D, Della Casa F, De Rosa F Biomedicines. 2022; 10(5).

PMID: 35625708 PMC: 9138211. DOI: 10.3390/biomedicines10050971.

Determination of immunogenic epitopes in major house dust mite allergen, Der p 2, via nanoallergens.

Sjoerdsma J, Mejia F, Bilgicer B Ann Allergy Asthma Immunol. 2022; 129(2):231-240.e2.

PMID: 35405356 PMC: 9808607. DOI: 10.1016/j.anai.2022.04.003.

Pediatric Dysfunctional Breathing: Proposed Components, Mechanisms, Diagnosis, and Management.

Barker N, Thevasagayam R, Ugonna K, Kirkby J Front Pediatr. 2020; 8:379.

PMID: 32766182 PMC: 7378385. DOI: 10.3389/fped.2020.00379.

Past, present, and future of allergen immunotherapy vaccines.

Dorofeeva Y, Shilovskiy I, Tulaeva I, Focke-Tejkl M, Flicker S, Kudlay D Allergy. 2020; 76(1):131-149.

PMID: 32249442 PMC: 7818275. DOI: 10.1111/all.14300.

References

Epstein T, Liss G, Murphy-Berendts K, Bernstein D . AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014; 2(2):161-7. DOI: 10.1016/j.jaip.2014.01.004. View

Tophof M, Hermanns A, Adelt T, Eberle P, Gronke C, Friedrichs F . Side effects during subcutaneous immunotherapy in children with allergic diseases. Pediatr Allergy Immunol. 2017; 29(3):267-274. DOI: 10.1111/pai.12847. View

Schoos A, Chawes B, Folsgaard N, Samandari N, Bonnelykke K, Bisgaard H . Disagreement between skin prick test and specific IgE in young children. Allergy. 2014; 70(1):41-8. DOI: 10.1111/all.12523. View

Wachholz P, Durham S . Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy. 2003; 33(9):1171-4. DOI: 10.1046/j.1365-2222.2003.01765.x. View

Passalacqua G, Baena-Cagnani C, Bousquet J, Canonica G, Casale T, Cox L . Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol. 2013; 132(1):93-8. DOI: 10.1016/j.jaci.2013.03.039. View

James L, Shamji M, Walker S, Wilson D, Wachholz P, Francis J . Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011; 127(2):509-516.e1-5. DOI: 10.1016/j.jaci.2010.12.1080. View

Eigenmann P, Atanaskovic-Markovic M, Hourihane J, Lack G, Lau S, Matricardi P . Testing children for allergies: why, how, who and when: an updated statement of the European Academy of Allergy and Clinical Immunology (EAACI) Section on Pediatrics and the EAACI-Clemens von Pirquet Foundation. Pediatr Allergy Immunol. 2013; 24(2):195-209. DOI: 10.1111/pai.12066. View

Till S, Francis J, Nouri-Aria K, Durham S . Mechanisms of immunotherapy. J Allergy Clin Immunol. 2004; 113(6):1025-34. DOI: 10.1016/j.jaci.2004.03.024. View

Akdis C, Akdis M . Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011; 127(1):18-27. DOI: 10.1016/j.jaci.2010.11.030. View

10.

Calderon M, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S . Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007; (1):CD001936. PMC: 7017974. DOI: 10.1002/14651858.CD001936.pub2. View

11.

Hatzler L, Panetta V, Lau S, Wagner P, Bergmann R, Illi S . Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012; 130(4):894-901.e5. DOI: 10.1016/j.jaci.2012.05.053. View

12.

Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Togias A . Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63 Suppl 86:8-160. DOI: 10.1111/j.1398-9995.2007.01620.x. View

13.

Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C . A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013; 17(27):vi, xi-xiv, 1-322. PMC: 4780904. DOI: 10.3310/hta17270. View

14.

Brozek J, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4):950-958. DOI: 10.1016/j.jaci.2017.03.050. View

15.

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I . Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2010; 127(1 Suppl):S1-55. DOI: 10.1016/j.jaci.2010.09.034. View

16.

Barber D, de la Torre F, Feo F, Florido F, Guardia P, Moreno C . Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study. Allergy. 2008; 63(11):1550-8. DOI: 10.1111/j.1398-9995.2008.01807.x. View

17.

Caminati M, Dama A, Djuric I, Montagni M, Schiappoli M, Ridolo E . Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Rev Clin Immunol. 2014; 11(2):233-45. DOI: 10.1586/1744666X.2015.988143. View

18.

Calderon M, Gerth van Wijk R, Eichler I, Matricardi P, Varga E, Kopp M . Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012; 23(4):300-6. DOI: 10.1111/j.1399-3038.2012.01313.x. View

19.

Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K . IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003; 33(5):1205-14. DOI: 10.1002/eji.200322919. View

20.

Schmid-Grendelmeier P, Crameri R . Recombinant allergens for skin testing. Int Arch Allergy Immunol. 2001; 125(2):96-111. DOI: 10.1159/000053803. View